Lemaitre Vascular Inc. (LMAT)
LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine
LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut
LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular Q2 Earnings Call Highlights
LeMaitre Vascular NASDAQ: LMAT reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign exchange, Middle East export delays and cardiac allograft supply constraints weighed on sales relative to management's expectations.
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.74 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.6 per share a year ago.
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre (LMAT) Upgraded to Buy: Here's Why
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.48 per share a year ago.
LeMaitre Vascular (LMAT)'s Technical Outlook is Bright After Key Golden Cross
After reaching an important support level, LeMaitre Vascular, Inc. (LMAT) could be a good stock pick from a technical perspective. LMAT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
